CD274 and Skin rash: Although most patients receiving anti-PD-1/PD-L1 therapy react with only mild toxicity profiles, including skin rash, dysthyroidism, and gastrointestinal events, more severe immune-mediated side effects occur in some patients, and treatment-related deaths have been reported [1, 2, 5].